The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).  

The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May. 

HTX-001 is a differentiated, potentially disease-modifying antisense oligonucleotide engineered to downregulate WISPER, a heart stress-specific lncRNA that is overexpressed in hypertrophic cardiomyopathy, including nHCM. By targeting WISPER in cardiac myofibroblasts, HTX-001 is intended to promote the precision reprogramming of this fibrotic and pathological cell state toward a healthy phenotype. 

“HAYA was founded on the belief that the regulatory genome offers a new way to address the underlying biology of disease,” said Samir Ounzain, CEO and Co-Founder of HAYA Therapeutics. “This regulatory designation recognises the potential of HTX-001 to offer a differentiated therapeutic approach for patients with nHCM.” 

“Patients with nonobstructive HCM are seeking treatments that go beyond management of symptoms. This designation reflects the urgency of delivering better therapeutic options,” said Dr Jordan Shin, CMO of HAYA Therapeutics. “With our Phase I clinical trial already underway, Fast Track designation allows us to work more closely with the FDA as we advance HTX-001, our investigational precision RNA-guided therapy designed to reprogramme disease-driving cardiac fibroblasts – the sentinel effector cells which act to drive fibrosis and remodelling in the myocardium.” 

The FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. This designation may enable more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval, priority review and rolling review. This is particularly important for patients with nHCM, which accounts for an estimated 30-60% of all hypertrophic cardiomyopathy cases, where current therapies do not directly target the fibrotic pathology or diastolic dysfunction that drive the disease.